Philips Genomics Workspace enables integration of the largest-scale FDA-cleared cancer genetic test at NYU Langone Health
On August 3, 2021, Philips announced a collaboration with NYU Langone Health to utilize the Philips Genomics Workspace for enhancing cancer treatment. This integration enables the industry's largest cancer sequencing test, the NYU Langone Genome PACT, which was recently FDA-cleared. The test analyzes 607 genes associated with various cancers, improving patient treatment decisions by utilizing next-generation sequencing (NGS) technology. Philips aims to facilitate seamless data sharing within the healthcare ecosystem.
- The collaboration integrates Philips Genomics Workspace with NYU Langone Health's EMR for improved patient care.
- The Genome PACT test is the largest cancer sequencing test approved by the FDA, covering 607 genes.
- Utilizes NGS technology, enhancing the ability to guide treatment decisions based on genomic data.
- None.
August 3, 2021
- Philips and NYU Langone Health Department of Pathology, a premier NCI (National Cancer Institute) designated comprehensive cancer center, collaborate for genomic processing, interpretation and reporting
- Leveraging Philips Genomics Workspace hosted on Philips HealthSuite, NGS (Next-Generation Sequencing) is integrated directly into NYU Langone’s EMR for seamless, secure data sharing and integrated decision-making
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that New York Langone Health’s Department of Pathology will leverage Philips Genomics Workspace (formerly part of IntelliSpace Precision Medicine Platform) to integrate into their EMR (electronic medical record) environment. This will enable the largest cancer sequencing test in the industry, helping to guide more confident treatment decisions and care pathways for patients who have received a cancer diagnosis.
Genetic test for all cancers designed by NYU Langone’s molecular pathologists
Cleared by the FDA (U.S. Food and Drug Administration) earlier this month under its 510(k) designation for clinical lab use, the NYU Langone Genome PACT (Profiling of Actionable Cancer Targets) test detects changes in the DNA code of 607 genes linked by past studies to the development of multiple types of cancer. The number of genes cancer types assayed is the largest among academic genomic sequencing tests of its kind.
PACT uses next-generation sequencing (NGS) technology, which can read the sequence of the molecular ‘letters’ making up DNA code within hundreds of genes simultaneously, and covers the most genes of any FDA-cleared NGS test to-date. The technology matches the genetics of each patient’s tumor cells with a growing number of approved therapies targeted to address specific sets of cancer-causing DNA changes.
“The work currently underway at NYU Langone is ground-breaking in the area of genomic sequencing and we are honored to be teaming on the development efforts, including building an interface between the new test and NYU Langone Health’s electronic medical records system,” said Louis Culot, General Manager of Oncology Informatics at Philips. “Philips Genomics Workspace, hosted on cloud-based Philips HealthSuite, will help facilitate the integration into the EMR so tests can be seamlessly ordered, reviewed, and shared by a patient’s care team.”
“PACT reaffirms the goal behind its design, which was to provide our patients with the best understanding of the genetic changes driving their cancers,” said PACT designer Matija Snuderl, MD, director of Molecular Pathology and Diagnostics in the Department of Pathology at NYU Langone Health. “Knowing the genetics of their tumor can help to determine which therapies will work for a given patient and their eligibility for specific clinical trials. Beyond the genetic changes that are important to the field now, we also wanted PACT to detect the changes anticipated to be important in diagnosis and treatment of cancer over the next five to ten years.”
Philips end-to-end oncology solutions driving a clear path to precision cancer care
According to the National Cancer Institute, patients today usually receive the same treatment as others who have same type and stage of cancer, despite growing evidence that they may respond differently [1]. Philips’ approach to precision medicine is to arm care teams with expert clinical guidance and a holistic view of the patient’s genotypic (the set of genes in the DNA) and phenotypic (observable characteristics influenced by environmental and lifestyle factors) information in order to make decisions efficiently, collaboratively and accurately. Recognizing the growing need for technological advancement in oncology care – from early detection to diagnosis to treatment to survivorship – Philips connects areas such as pathology, genomics, molecular/multi-disciplinary tumor boards, therapy decision making, molecular and imaging phenotyping, so clinicians can have easy access to the insights they need to provide high-quality personalized care.
With Philips Genomics Workspace, oncologists can map a patient’s unique characteristics to a therapy that is best suited for them and provide evidence on why that therapy is preferable. Philips genomics solution combines individual institution genomic knowledge bases and general industry knowledge bases, to help molecular pathologists interpret genomic data and to provide clinicians with ways to enable improved patient care. Visit Philips Precision Medicine to learn more.
[1] https://www.cancer.gov/about-cancer/treatment/types/biomarker-testing-cancer-treatment.
For further information, please contact:
Kathy O’Reilly
Philips Global Press Office
Tel.: + 1 978-221-8919
E-mail: kathy.oreilly@philips.com
Twitter: @kathyoreilly
Greg Williams
Research Communications Director
NYU Grossman School of Medicine
Tel: +1 212-404-3500
E-mail: Gregory.williams@nyulangone.org
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 17.3 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Attachments
FAQ
What is the partnership between Philips and NYU Langone Health about?
What is the Genome PACT test announced by Philips?
How does the Philips Genomics Workspace improve cancer treatment?
When was the Genome PACT test FDA-cleared?
What technology does the Genome PACT test use?
